One-Hour Fingerstick Test Could Save Millions From Hepatitis B

For millions living with hepatitis B in remote areas, getting tested has meant traveling hours to clinics, giving blood samples, and waiting weeks for results that might never come. Australian scientists just changed that with a fingerstick test that works in an hour.

Researchers at the Kirby Institute at the University of New South Wales completed the world's first trial proving a point-of-care fingerstick test matches the accuracy of traditional laboratory testing. The study, published in the Journal of Clinical Microbiology, showed the test can be performed in small local clinics by regular healthcare workers.

The difference is life-changing for patients. Instead of needing venous blood draws sent to distant labs, a simple finger prick provides results in 60 minutes. No more long trips, no more anxious waiting, no more patients lost to follow-up because the process felt impossible.

Professor Gail Matthews, who led the research, said the test could "expand access to testing and treatment globally," especially in areas where laboratory testing remains out of reach. For many communities, this transforms hepatitis B care from theoretical to actually achievable.

The timing matters desperately. Hepatitis B affects 254 million people worldwide and kills over 1 million annually, yet only 8 percent of those with chronic infections receive treatment according to the World Health Organization. The virus attacks the liver and is preventable by vaccine, but reaching people who already have it requires accessible testing.

Current hepatitis B DNA testing creates barriers at every step. Patients must travel to facilities equipped for venous blood draws, samples must reach centralized laboratories, and results take days or weeks to return. Each delay means more people slip through the cracks, their infections progressing untreated.

The new fingerstick approach removes those obstacles. Small health clinics can now offer immediate testing without specialized lab equipment. Healthcare workers with basic training can perform the test, and patients walk out knowing their status the same day they walk in.

The Ripple Effect

This breakthrough positions the world to actually meet the WHO's 2030 target for eliminating hepatitis B as a public health threat. Similar point-of-care tests already transformed hepatitis C care, but until now nobody knew if the approach would work for hepatitis B DNA using fingerstick blood.

The Australian trial proved it does. Remote villages, resource-limited clinics, and underserved communities can now offer the same quality testing as major medical centers. The technology exists, it works, and it's ready to scale.

For the 92 percent of hepatitis B patients worldwide who aren't getting treatment, this simple test opens a door that laboratory requirements kept locked. Testing is the first step toward treatment, and treatment saves lives.